CLEVELAND, Ohio (Ivanhoe Newswire) - Heart disease is the leading cause of death in the U.S. More than a quarter of Americans over the age of 40 are taking a statin to lower their cholesterol and to ...

There's two promising options to make statins tolerable again.

CHICAGO, IL (updated) — Six-month treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (Repatha, Amgen) can dramatically reduce LDL-cholesterol levels in ...

An AI framework developed by Nashville, Tenn.-based Vanderbilt University identified statin intolerance, contraindications and patient deferrals documented in clinical notes for 10% of adult patients.

Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to Esperion's key opinion leader Investor event, Breaking the Statin ...

CLEVELAND, Ohio (Ivanhoe Newswire) – Heart disease is the leading cause of death in the United States. More than a quarter of Americans over the age of 40 are taking a statin to lower their ...

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ...

An alternative option for patients who have tried several statins and experienced recurrent myalgia is to initiate a more potent statin, such as atorvastatin or rosuvastatin, on an every-other-day or ...

– Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes – ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced ...